MedTrace Logo

Vivifi Device Safety Evaluation for the Treatment of Benign Prostatic Hyperplasia

NCT07745621 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-08-04

No results posted yet for this study

Summary

The study objective is to evaluate the safety and feasibility of the Vivifi device to treat symptomatic, benign prostatic hyperplasia (BPH).

Conditions

  • Benign Prostatic Hyperplasia

Interventions

DEVICE

Minimally invasive percutaneous ablation

Percutaneous ablation will be used to modify the vascular supply to the prostate via a minimally invasive scrotal approach

Sponsors & Collaborators

  • RQM Plus

    collaborator UNKNOWN

  • Vivifi Medical

    lead INDUSTRY

Principal Investigators

  • Daniel Root, MD

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2027-02-28
Completion
2028-12-31

Countries

  • Panama

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07745621 on ClinicalTrials.gov